Literature DB >> 16043102

Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria.

Kelly Hamman1, Heather Clark, Eugenio Montini, Muhsen Al-Dhalimy, Markus Grompe, Milton Finegold, Cary O Harding.   

Abstract

Phenylalanine homeostasis in mammals is primarily controlled by liver phenylalanine hydroxylase (PAH) activity. Inherited PAH deficiency (phenylketonuria or PKU) leads to hyperphenylalaninemia in both mice and humans. A low level of residual liver PAH activity ensures near-normal dietary protein tolerance with normal serum phenylalanine level, but the precise threshold for normal phenylalanine clearance is unknown. We employed hepatocyte transplantation under selective growth conditions to investigate the minimal number of PAH-expressing hepatocytes necessary to prevent hyperphenylalaninemia in mice. Serum phenylalanine levels remained normal in mice exhibiting nearly complete liver repopulation with PAH-deficient hepatocytes (<5% residual wild-type liver PAH activity). Conversely, transplantation of PAH-positive hepatocytes into PAH-deficient Pah(enu2) mice, a model of human PKU, yielded a significant decrease in serum phenylalanine (<700 muM) when liver repopulation exceeded approximately 5%. These data suggest that restoration of phenylalanine homeostasis requires PAH activity in only a minority of hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16043102      PMCID: PMC2694052          DOI: 10.1016/j.ymthe.2005.03.025

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  25 in total

1.  The enzymatic conversion of phenylalanine to tyrosine.

Authors:  S UDENFRIEND; J R COOPER
Journal:  J Biol Chem       Date:  1952-02       Impact factor: 5.157

2.  Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation.

Authors:  I J Fox; J R Chowdhury; S S Kaufman; T C Goertzen; N R Chowdhury; P I Warkentin; K Dorko; B V Sauter; S C Strom
Journal:  N Engl J Med       Date:  1998-05-14       Impact factor: 91.245

3.  Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.

Authors:  M Al-Dhalimy; K Overturf; M Finegold; M Grompe
Journal:  Mol Genet Metab       Date:  2002-01       Impact factor: 4.797

4.  Characterization of mutations at the mouse phenylalanine hydroxylase locus.

Authors:  J D McDonald; C K Charlton
Journal:  Genomics       Date:  1997-02-01       Impact factor: 5.736

5.  RAG-1-deficient mice have no mature B and T lymphocytes.

Authors:  P Mombaerts; J Iacomini; R S Johnson; K Herrup; S Tonegawa; V E Papaioannou
Journal:  Cell       Date:  1992-03-06       Impact factor: 41.582

6.  Metabolic engineering as therapy for inborn errors of metabolism--development of mice with phenylalanine hydroxylase expression in muscle.

Authors:  C O Harding; K Wild; D Chang; A Messing; J A Wolff
Journal:  Gene Ther       Date:  1998-05       Impact factor: 5.250

7.  Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I.

Authors:  K Overturf; M Al-Dhalimy; R Tanguay; M Brantly; C N Ou; M Finegold; M Grompe
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

8.  Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice.

Authors:  M Grompe; M al-Dhalimy; M Finegold; C N Ou; T Burlingame; N G Kennaway; P Soriano
Journal:  Genes Dev       Date:  1993-12       Impact factor: 11.361

9.  Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer.

Authors:  B Fang; R C Eisensmith; X H Li; M J Finegold; A Shedlovsky; W Dove; S L Woo
Journal:  Gene Ther       Date:  1994-07       Impact factor: 5.250

10.  Reconstitution of enzymatic activity in hepatocytes of phenylalanine hydroxylase-deficient mice.

Authors:  T J Liu; M A Kay; G J Darlington; S L Woo
Journal:  Somat Cell Mol Genet       Date:  1992-01
View more
  22 in total

1.  Advances and challenges in phenylketonuria.

Authors:  Cary O Harding; Nenad Blau
Journal:  J Inherit Metab Dis       Date:  2010-12       Impact factor: 4.982

Review 2.  State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.

Authors:  Hiu Man Grisch-Chan; Gerald Schwank; Cary O Harding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2019-09-09       Impact factor: 5.695

3.  Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU).

Authors:  Kelly J Hamman; Shelley R Winn; Cary O Harding
Journal:  Mol Genet Metab       Date:  2011-08-04       Impact factor: 4.797

4.  Treatment of phenylketonuria using minicircle-based naked-DNA gene transfer to murine liver.

Authors:  Hiu Man Viecelli; Richard P Harbottle; Suet Ping Wong; Andrea Schlegel; Marinee K Chuah; Thierry VandenDriessche; Cary O Harding; Beat Thöny
Journal:  Hepatology       Date:  2014-07-29       Impact factor: 17.425

5.  Hepatocyte transplantation (HTx) corrects selected neurometabolic abnormalities in murine intermediate maple syrup urine disease (iMSUD).

Authors:  Kristen J Skvorak; Elizabeth J Hager; Erland Arning; Teodoro Bottiglieri; Harbhajan S Paul; Stephen C Strom; Gregg E Homanics; Qin Sun; Erwin E W Jansen; Cornelis Jakobs; William J Zinnanti; K Michael Gibson
Journal:  Biochim Biophys Acta       Date:  2009-08-19

Review 6.  Progress toward cell-directed therapy for phenylketonuria.

Authors:  Co Harding
Journal:  Clin Genet       Date:  2008-05-21       Impact factor: 4.438

7.  Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver disease.

Authors:  Raymond D Hickey; Shennen A Mao; Jaime Glorioso; Joseph B Lillegard; James E Fisher; Bruce Amiot; Piero Rinaldo; Cary O Harding; Ronald Marler; Milton J Finegold; Markus Grompe; Scott L Nyberg
Journal:  Stem Cell Res       Date:  2014-05-14       Impact factor: 2.020

8.  A novel Pah-exon1 deleted murine model of phenylalanine hydroxylase (PAH) deficiency.

Authors:  Daelyn Y Richards; Shelley R Winn; Sandra Dudley; Lev Fedorov; Nicole Rimann; Beat Thöny; Cary O Harding
Journal:  Mol Genet Metab       Date:  2020-09-30       Impact factor: 4.797

9.  Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice.

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Ming Ying; Aurora Martinez; Sydney Weber; Jacob Raber; Cary O Harding
Journal:  Mol Genet Metab       Date:  2017-10-19       Impact factor: 4.797

10.  Placental stem cell correction of murine intermediate maple syrup urine disease.

Authors:  Kristen J Skvorak; Kenneth Dorko; Fabio Marongiu; Veysel Tahan; Marc C Hansel; Roberto Gramignoli; K Michael Gibson; Stephen C Strom
Journal:  Hepatology       Date:  2013-02-15       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.